Monoamine Transporter (Serotonin Transporter, Dopamine Transporter, and Norepinephrine Transporter) (MAT)

The monoamine transporters (MATs) comprise three distinct proteins: the serotonin transporter (SERT/SLC6A4), the dopamine transporter (DAT/SLC6A3), and the norepinephrine transporter (NET/SLC6A2) [UniProt P31645, Q01959, P23975]. These transporters are responsible for the sodium- and chloride-dependent reuptake of monoamine neurotransmitters from the synaptic cleft back into presynaptic neurons, thereby regulating the duration and intensity of synaptic signaling [StatPearls: Physiology, Monoamine Transporters]. SERT, DAT, and NET play pivotal roles in modulating mood, reward, attention, and autonomic functions, making them central to the pathophysiology of major depressive disorder, ADHD, and obesity [PubMed: PMC3181613]. Drugs that target all three transporters, known as triple reuptake inhibitors (SNDRIs), aim to provide enhanced therapeutic efficacy by simultaneously elevating serotonin, dopamine, and norepinephrine levels [PubMed: PMC2697132]. This broad mechanism is hypothesized to offer a faster onset of action and better management of treatment-resistant symptoms compared to selective inhibitors [NIH: Neurotransmitter Transporters]. However, the pharmacological challenge lies in balancing the inhibition ratios to avoid significant cardiovascular side effects or abuse potential associated with excessive dopamine and norepinephrine elevation [PubMed: PMC4258993]. Clinical candidates like tesofensine and centanafadine exemplify the ongoing effort to leverage this multi-target approach for complex neuropsychiatric and metabolic conditions [ClinicalTrials.gov].

Other names

SLC6A2/3/4Triple reuptake transportersSodium-dependent monoamine transportersSERT/DAT/NET

Inhibition of the reuptake of serotonin, dopamine, and norepinephrine from the synaptic cleft into the presynaptic neuron by binding to and blocking the respective transporter proteins (SERT, DAT, and NET).